Light Horse Therapeutics
Light Horse Therapeutics employs a function-first approach utilizing proprietary precision gene editing and target-agnostic functional screens to discover novel therapeutic targets. This platform identifies cryptic, chemically accessible functional domains within biologic targets that drive disabling diseases. The company develops small molecule drugs to disrupt these root causes, initially focusing on challenging oncology targets.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$62MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Markus Renschler
CEO
Product
Features
- Light Horse Therapeutics employs a function-first approach utilizing proprietary precision gene editing and target-agnostic functional screens to discover novel therapeutic targets. This platform identifies cryptic, chemically accessible functional domains within biologic targets that drive disabling diseases. The company develops small molecule drugs to disrupt these root causes, initially focusing on challenging oncology targets.